WallStreetZenWallStreetZen

NASDAQ: MNMD
Mind Medicine Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for MNMD

Based on 5 analysts offering 12 month price targets for Mind Medicine Inc

Min Forecast
$16.00+150.39%
Avg Forecast
$26.80+319.41%
Max Forecast
$55.00+760.72%

Should I buy or sell MNMD stock?

Based on 5 analysts offering ratings for Mind Medicine Inc.

Buy
Strong Buy
1 analysts 20%
Buy
4 analysts 80%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although MNMD's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates MNMD as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their MNMD stock forecasts and price targets.

MNMD stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-07
lockedlocked$00.00+00.00%2025-03-07
lockedlocked$00.00+00.00%2025-01-28
lockedlocked$00.00+00.00%2024-12-20
lockedlocked$00.00+00.00%2024-12-17

1 of 1

Forecast return on equity

Is MNMD forecast to generate an efficient return?

Company
29.97%
Industry
142.9%
Market
80.27%
MNMD's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MNMD forecast to generate an efficient return on assets?

Company
23.95%
Industry
35.65%
MNMD is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MNMD earnings per share forecast

What is MNMD's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$1.55
Avg 2 year Forecast
-$1.65
Avg 3 year Forecast
-$0.58

MNMD revenue forecast

What is MNMD's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$242.1M
Avg 2 year Forecast
$455.0M
Avg 3 year Forecast
$1.2B

MNMD vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MNMD$6.39$26.80+319.41%Buy
RGNX$9.61$31.00+222.58%Buy
TBPH$9.77$15.00+53.53%Buy
ZBIO$11.58$32.25+178.50%Strong Buy
CGEM$8.28$34.00+310.63%Strong Buy
View Top Biotech Stocks

Mind Medicine Stock Forecast FAQ

Is Mind Medicine Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: MNMD) stock is to Buy MNMD stock.

Out of 5 analysts, 1 (20%) are recommending MNMD as a Strong Buy, 4 (80%) are recommending MNMD as a Buy, 0 (0%) are recommending MNMD as a Hold, 0 (0%) are recommending MNMD as a Sell, and 0 (0%) are recommending MNMD as a Strong Sell.

If you're new to stock investing, here's how to buy Mind Medicine stock.

What is MNMD's earnings growth forecast for 2025-2027?

(NASDAQ: MNMD) Mind Medicine's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.59%.

Mind Medicine's earnings in 2025 is -$108,679,000.On average, 5 Wall Street analysts forecast MNMD's earnings for 2025 to be -$116,519,483, with the lowest MNMD earnings forecast at -$128,126,210, and the highest MNMD earnings forecast at -$106,269,386. On average, 3 Wall Street analysts forecast MNMD's earnings for 2026 to be -$124,109,077, with the lowest MNMD earnings forecast at -$137,924,097, and the highest MNMD earnings forecast at -$113,806,222.

In 2027, MNMD is forecast to generate -$43,713,648 in earnings, with the lowest earnings forecast at -$105,515,703 and the highest earnings forecast at $72,353,625.

What is MNMD's revenue growth forecast for 2027-2029?

(NASDAQ: MNMD) Mind Medicine's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.

Mind Medicine's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast MNMD's revenue for 2027 to be $18,249,694,448, with the lowest MNMD revenue forecast at $6,285,721,141, and the highest MNMD revenue forecast at $30,213,667,756. On average, 3 Wall Street analysts forecast MNMD's revenue for 2028 to be $34,294,864,396, with the lowest MNMD revenue forecast at $6,353,552,664, and the highest MNMD revenue forecast at $71,523,819,007.

In 2029, MNMD is forecast to generate $89,086,530,863 in revenue, with the lowest revenue forecast at $61,161,423,329 and the highest revenue forecast at $117,011,638,398.

What is MNMD's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: MNMD) forecast ROA is 23.95%, which is lower than the forecast US Biotechnology industry average of 35.65%.

What is MNMD's Price Target?

According to 5 Wall Street analysts that have issued a 1 year MNMD price target, the average MNMD price target is $26.80, with the highest MNMD stock price forecast at $55.00 and the lowest MNMD stock price forecast at $16.00.

On average, Wall Street analysts predict that Mind Medicine's share price could reach $26.80 by Mar 7, 2026. The average Mind Medicine stock price prediction forecasts a potential upside of 319.41% from the current MNMD share price of $6.39.

What is MNMD's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: MNMD) Mind Medicine's current Earnings Per Share (EPS) is -$1.54. On average, analysts forecast that MNMD's EPS will be -$1.55 for 2025, with the lowest EPS forecast at -$1.70, and the highest EPS forecast at -$1.41. On average, analysts forecast that MNMD's EPS will be -$1.65 for 2026, with the lowest EPS forecast at -$1.83, and the highest EPS forecast at -$1.51. In 2027, MNMD's EPS is forecast to hit -$0.58 (min: -$1.40, max: $0.96).

What is MNMD's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: MNMD) forecast ROE is 29.97%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.